Investment Rating - The cosmetics industry is rated as "Outperform" compared to the market [3] Core Viewpoints - The overall performance of the cosmetics industry has been relatively weak due to internal and external factors, but some companies have achieved impressive revenue and net profit growth through strong product capabilities and flexible marketing strategies. With the gradual economic recovery and the introduction of consumption-boosting policies, further demand recovery is expected in the second half of the year. In the medium to long term, some domestic beauty brands are enhancing R&D investment and standing out due to their outstanding product capabilities amid the rise of domestic trends. Additionally, stricter industry regulations are favorable for compliant leading enterprises. It is recommended to focus on domestic cosmetics leaders with strong R&D, product strength, and marketing capabilities [1][2] Summary by Sections Market Performance - From January 1, 2025, to May 6, 2025, the cosmetics sector rose by 29.07%, significantly outperforming the CSI 300 index by 32.28 percentage points. The brand segment increased by 31.08%, while the raw materials segment faced a decline of 20.37% [10][13] - Individual stock performance highlights include Bawei Co. leading the OEM segment, Ruoyuchen leading the operation segment, and Jinbo Biological, Marubi, and Shanghai Jahwa leading the brand segment [13][14] Financial Performance - Revenue and net profit: The raw materials segment faced pressure, while some leading companies in the OEM and brand segments showed impressive performance. For instance, Bawei Co. reported a revenue increase of 48.27% and a net profit increase of 10.28% in 2024 [16][17] - Gross and net profit margins: Most beauty companies saw an increase in gross margins in Q1 2025. Qing Song Co. improved its profitability due to continuous innovation in cosmetic raw materials and product formula optimization [20][21] - Inventory turnover and operating capital turnover: Bawei Co. had the highest inventory turnover rate in the cosmetics sector at 6.93 times, while the operating capital turnover rate for the brand segment was also generally above 1 [23] Valuation Situation - The valuation levels of individual stocks are varied. In 2025, the PE ratios for leading companies like Lafang and Ruoyuchen are relatively high at 64 and 49 times, respectively, while companies like Kesi and Fulejia have lower PE ratios of 17 and 18 times [2]

沪指5月9日下跌0.30%，申万所属行业中，今日上涨的有7个，涨幅居前的行业为美容护理、银行，涨 幅分别为1.41%、1.36%。美容护理行业位居今日涨幅榜首位。跌幅居前的行业为电子、计算机，跌幅 分别为2.07%、1.96%。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002094 | 青岛金王 | -4.17 | 23.74 | -4096.76 | | 603193 | 润本股份 | 4.77 | 5.32 | -868.93 | | 300856 | 科思股份 | -0.10 | 1.41 | -840.98 | | 603983 | 丸美生物 | 5.38 | 1.38 | -801.90 | | 301009 | 可靠股份 | -1.81 | 4.65 | -779.05 | | 300896 | 爱美客 | -0.38 | 1.26 | -750.74 | | 300132 | 青松股份 | 0.18 | 2.76 | -553.39 | | 002511 | 中顺洁柔 | 1 ...

证券代码：300856 证券简称：科思股份 公告编号：2025-030 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 关于预计触发科思转债转股价格向下修正条件的提示 性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300856 证券简称：科思股份 2、债券代码：123192 债券简称：科思转债 3、转股价格：24.64 元/股 4、转股期限：2023 年 10 月 19 日至 2029 年 4 月 12 日（如遇法 定节假日或休息日延至其后的第 1 个工作日） 经中国证券监督管理委员会《关于同意南京科思化学股份有限公 司向不特定对象发行可转换公司债券注册的批复》（证监许可 [2023]680 号）同意，公司向不特定对象发行可转债 7,249,178 张， 每张面值为人民币 100.00 元，按面值发行，发行总额为人民币 724,917,800.00 元。扣除不含税发行费用后,本次发行募集资金净额 为人民币 716,332,190.67 元。 （二）可转债上市情况 经深圳证券交易所同意，公司可转债于 20 ...

证券代码：300856 证券简称：科思股份 公告编号：2025-031 债券代码：123192 债券简称：科思转债 欢迎广大投资者积极参与。 （问题征集专题页面二维码） 特此公告。 南京科思化学股份有限公司董事会 南京科思化学股份有限公司 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 南京科思化学股份有限公司（以下简称"公司"）《2024 年年度报 告 》 及 其 摘 要 已 于 2025 年 4 月 23 日在巨潮资讯网 （www.cninfo.com.cn）上披露。为使广大投资者更全面深入地了解 公司 2024 年度的经营情况，公司将于 2025 年 5 月 13 日（星期二） 15:00-17:00 举办 2024 年度业绩说明会。本次说明会将采用网络远 程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事兼总裁杨军先生、独立董事 宋兵先生、财务总监孟海斌先生和董事会秘书陈家伟先生以及保荐代 表人王风雷先生。 ...

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1] Core Views - The company's short-term performance is under pressure due to factors such as inventory adjustments and price changes, but long-term growth is expected to be driven by the launch of new products [8] - The company is a global leader in cosmetic raw materials, and while 2024's performance is affected by the downstream inventory cycle, the penetration of new sunscreen agents is a long-term industry trend [8] - The company has sufficient capacity reserves and is actively expanding production, particularly in Malaysia, which will enhance its risk resistance and internationalization [8] Financial Summary - In 2024, the company is projected to achieve total revenue of 22.76 billion yuan, a decrease of 5.16% year-on-year, and a net profit attributable to shareholders of 5.62 billion yuan, down 23.33% [8] - The gross margin for 2024 and Q1 2025 is expected to be 44.40% and 34.04%, respectively, reflecting a decline due to price adjustments in sunscreen products [8] - The company's earnings per share (EPS) for 2024 is projected at 1.66 yuan, with a price-to-earnings (P/E) ratio of 12.61 [1][9]

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1] Core Views - The company's short-term performance is under pressure due to factors such as inventory adjustments and price changes, but there is optimism for long-term growth driven by new product launches [1][8] - The company is a leading global player in cosmetic raw materials, and while 2024's performance is affected by the downstream inventory cycle, the increasing penetration of new sunscreen agents is a long-term industry trend [8] - The company has sufficient capacity reserves and is actively expanding production, particularly in Malaysia, which will enhance its risk resistance and international presence [8] Financial Summary - Total revenue for 2024 is projected at 22.76 billion yuan, a decrease of 5.16% year-on-year, with a net profit of 5.62 billion yuan, down 23.33% [8] - The gross margin for 2024 is expected to be 44.40%, while the net profit margin is projected at 24.65% [8] - The company's earnings per share (EPS) for 2024 is estimated at 1.66 yuan, with a price-to-earnings (P/E) ratio of 12.61 [1][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][15] Core Views - The company's performance is under pressure due to downstream inventory destocking and price reductions, with expectations for demand recovery and new product ramp-up in the future [1][7] - In 2024, the company achieved revenue of 2.28 billion yuan, a year-on-year decrease of 5.2%, and a net profit attributable to the parent company of 560 million yuan, down 23.3% year-on-year [7][10] - The forecast for net profit for 2025-2027 is adjusted to 410 million, 526 million, and 637 million yuan respectively, with year-on-year changes of -27.2%, +28.3%, and +21.2% [7][10] Financial Performance - The company's revenue for 2024 is projected at 2.15 billion yuan, with a year-on-year decline of 5.5% [10] - The gross margin for 2024 is expected to be 36.8%, down from 44.4% in 2023 [10] - The net profit margin is projected to decrease to 19.1% in 2025 from 24.7% in 2024 [10] Business Segments - Revenue from cosmetic active ingredients and their raw materials is expected to be 1.9 billion yuan in 2024, down 8.1% year-on-year, while synthetic fragrance revenue is projected at 350 million yuan, up 14.2% year-on-year [8] - The domestic market shows a bright performance, with domestic revenue increasing by 22.87% year-on-year, while overseas revenue is expected to decline by 8.3% [8] Capacity and Expansion - The company has made progress in expanding its product lines, with new production lines for high-end personal care products and sunscreen series products under construction [9][10] - The capacity utilization rates for cosmetic active ingredients and synthetic fragrances are 54.98% and 89.22% respectively in 2024 [8] Valuation Metrics - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 17.3, 13.5, and 11.1 respectively [10] - The price-to-book (P/B) ratios for the same years are expected to be 2.3, 2.1, and 1.9 [10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][15] Core Views - The company's performance is under pressure due to downstream inventory destocking and price reductions, with expectations for demand recovery and new product ramp-up [1][7] - In 2024, the company achieved revenue of 2.28 billion yuan, a year-on-year decrease of 5.2%, and a net profit attributable to the parent company of 560 million yuan, down 23.3% year-on-year [7][10] - The forecast for net profit for 2025-2027 is adjusted to 410 million, 526 million, and 637 million yuan respectively, with year-on-year changes of -27.2%, +28.3%, and +21.2% [7][10] Financial Summary - The current stock price is 19.88 yuan, with a market capitalization of 6.755 billion yuan [3] - The company's revenue and net profit projections for 2025 and 2026 are 2.15 billion and 2.58 billion yuan, and 410 million and 526 million yuan respectively [10][12] - The gross margin for 2024 is 44.4%, down 4.43 percentage points year-on-year, while the net margin is 24.65%, down 5.92 percentage points year-on-year [9][10] Business Performance - The company's sunscreen product shipments have declined due to slowing market demand and customer inventory digestion, with some product prices also decreasing [7][8] - The revenue from cosmetic active ingredients and synthetic fragrances in 2024 is 1.9 billion and 350 million yuan, with year-on-year changes of -8.1% and +14.2% respectively [8] - The company is expanding its product lines and steadily progressing with new products, including a new high-end personal care product project with an annual capacity of 2,600 tons [9][10]

标段名称：云南省疾控中心超级微波消解系统采购项目（2025-13）1标段 供应商名称：昆明超泰经贸有限公司 供应商地址：云南省昆明市盘龙区铂金大道云南映象城市公园广场6栋1805室 中标金额(万元)：117.9 评标方式：综合评分法 评审总得分：89.63 四、主要标的信息 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 AI大潮袭来，唯有学习方能不被淘汰。 全新升级版 的 AI学习资料包 免费下载：《 AI资料包升级版新增厦大湖南大学等》 一、项目编号:YNZC2025-G1-00945-QHZX-0013 二、项目名称： 云南省疾控中心超级微波消解系统采购项目（2025-13） 三、中标信息 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 子 领取方式：关注本号，后台回复" ...

证券代码：300856 证券简称：科思股份 公告编号：2025-013 债券代码：123192 债券简称：科思转债 一、募集资金基本情况 （一）首次公开发行股票募集资金 1、实际募集资金金额及到位情况 根据中国证券监督管理委员会证监许可【2020】803 号《关于核 准南京科思化学股份有限公司首次公开发行股票的批复》文件核准， 南京科思化学股份有限公司（以下简称"公司""本公司"）由主承销 商民生证券股份有限公司（以下简称"民生证券"）向社会公众公开 发行人民币普通股（A 股）2,822 万股，每股面值 1.00 元，发行价为 每股 30.56 元，共募集资金 86,240.32 万元，扣除发行费用 7,727.21 万元后，实际募集资金净额为 78,513.11 万元。上述募集资金到位情 况已经天衡会计师事务所（特殊普通合伙）出具的天衡验字（2020） 00071 号《验资报告》验证。 南京科思化学股份有限公司 2、以前年度募集资金使用及结余情况 2024 年度募集资金存放与使用情况的专项报告 截至 2023 年 12 月 31 日，本公司累计使用募集资金 68,120.06 万元，募集资金专户余额为 2, ...